Phase 2 ELEKTRA Study Design
- United States
Phase 2 ELEKTRA Study of Soticlestat (TAK-935/OV935) Meets Primary Endpoint Reducing Seizure Frequency in Children with Dravet Syndrome or Lennox-Gastaut Syndrome
Osaka, Japan & New York, United States: − Primary endpoint achieved, demonstrating a statistically significant reduction of seizures from baseline compared…
Read More »